X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
KRAZATI (adagrasib) is a highly selective and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, being evaluated in Phase III clinical trial studies for the treatment of locally advanced or metastatic non-small cell lung cancer.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Krazati (adagrasib) is highly selective and potent oral small-molecule inhibitor of KRAS G12C. It is being evaluated for treatment of patients with KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
Krazati (adagrasib) is highly selective and potent oral small-molecule inhibitor of KRA SG12C. It is being evaluated for treatment of patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab,BMS-986466
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
Through the acquisition, BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor approved by the U.S. FDA for the treatment of patients with advanced non-small cell lung cancer harboring a KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $5,800.0 million Upfront Cash: $5,800.0 million
Deal Type: Acquisition January 23, 2024
Details:
The collaboration aims to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC).
Lead Product(s): KO-2806,Adagrasib
Therapeutic Area: Oncology Product Name: KO-2806
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2023
Details:
Through the acquisition, BMS strengthens and diversifies oncology portfolio by gaining Krazati (adagrasib), a best-in-class KRASG12C inhibitor approved by the U.S. FDA for the treatment of patients with advanced non-small cell lung cancer harboring a KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $5,800.0 million Upfront Cash: $5,800.0 million
Deal Type: Acquisition October 08, 2023
Details:
Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated for colorectal cancer.
Lead Product(s): Adagrasib,Cetuximab
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2023
Details:
Krazati (adagrasib) is an investigational, highly selective and potent oral small molecule inhibitor of KRASG12C that is optimized to sustain target inhibition. It is indicated for the treatment KRASG12C-mutated NSCLC and currently is being investigated for colorectal cancer.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Krazati (adagrasib), is being evaluated in several clinical trials in combination with other anti-cancer therapies with strong scientific rationale in patients with advanced solid tumors. Lung cancer is one of the world’s most widespread cancers.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Qiagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Mirati has risen to meet one of the most challenging mutations in cancer research by developing KRAZATI, a highly selective and potent oral small-molecule inhibitor of KRASG12C.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Krazati
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
INCB99280 is a potent and selective small molecule oral PD-L1 inhibitor which has demonstrated promising clinical activity and safety in patients with solid tumors.
Lead Product(s): INCB99280,Adagrasib
Therapeutic Area: Oncology Product Name: INCB99280
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 07, 2022
Details:
ABI-009 (Nab-sirolimus) is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Lead Product(s): Nab-sirolimus,Sotorasib,Adagrasib
Therapeutic Area: Oncology Product Name: ABI-009
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Under the terms of the collaboration agreement, Mirati will be responsible for sponsoring and operating the Phase 1/2 study of Adagrasib (MRTX849), and jointly with Aadi, will oversee and share the cost of the study.
Lead Product(s): Adagrasib,Nab-sirolimus
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2022
Details:
MRTX849 (adagrasib) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition, to treat KRASG12C-mutated cancers, as KRASG12C protein regenerates every 24–48 hours.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
NDA is based on the Phase 2 KRYSTAL-1 study, evaluating adagrasib, small-molecule inhibitor of KRASG12C, 600mg BID in patients with advanced NSCLC harboring the KRASG12C mutation following prior treatment with immunotherapy and chemotherapy, either together or sequentially.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
This clinical collaboration agreement will initiate to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Lead Product(s): Adagrasib,VS-6766
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Verastem Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 22, 2021
Details:
Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 10, 2021
Details:
Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
Under the terms of the agreement, Sanofi will be responsible for sponsoring and operating the Phase 1/2 study, and jointly with Mirati, will oversee and share costs of the study.
Lead Product(s): Adagrasib,Vociprotafib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 07, 2021
Details:
Phase 1/2 KRYSTAL-1 study evaluating adagrasib, an oral small-molecule inhibitor of KRASG12C at 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2021
Details:
Adagrasib is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C, optimized to sustain target inhibition, an attribute that could be important to treat KRASG12C mutated cancers, as the KRASG12C protein regenerates every 24-48 hours.
Lead Product(s): Adagrasib,Pembrolizumab
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
Zai Lab obtains the right to research, develop, manufacture and exclusively commercialize adagrasib in Greater China. Agreement will accelerate enrollment in key global, registration-enabling clinical trials investigating adagrasib in patients with KRAS G12C mutations.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: $338.0 million Upfront Cash: $65.0 million
Deal Type: Collaboration June 01, 2021
Details:
QIAGEN is developing a tissue-based companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2021
Details:
The collaboration aims to expand the evaluation of Mirati's two investigational small molecule, adagrasib, a G12C inhibitor in clinical development, and MRTX1133 as monotherapy and in combination with other agents for two of the most frequent KRAS mutations in cancer.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2021
Details:
At the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics last week, Mirati presented preliminary adagrasib (MRTX849) data across multiple tumors, which highlighted the potential for this exciting and differentiated program.
Lead Product(s): Adagrasib,Pembrolizumab
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Clinical data from adagrasib (MRTX849), the Company's KRAS G12C selective inhibitor, will be presented at the EORTC-NCI-AACR International Virtual Conference on Molecular Targets and Therapeutics on October 25, 2020.
Lead Product(s): Adagrasib,Pembrolizumab
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patients.
Lead Product(s): BI 1701963,Adagrasib
Therapeutic Area: Oncology Product Name: BI 1701963
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 17, 2020
Details:
Under the terms of the agreement, Strata Oncology will identify patients with advanced solid tumors who have a KRAS G12C mutation and meet other eligibility criteria, to be considered for enrollment into Mirati's Phase 1/2 study, MRTX849-001 a G12C selective inhibitor.
Lead Product(s): Adagrasib,Pembrolizumab,Cetuximab
Therapeutic Area: Oncology Product Name: MRTX849
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 13, 2020
Details:
The data to be presented will include preclinical findings on MRTX849, a novel and optimized KRAS G12C inhibitor.
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Mirati expects to use funds for general corporate purposes, including expenses related to clinical development of MRTX849 and sitravatinib, manufacturing scale-up, the preclinical development of KRAS G12D inhibitor
Lead Product(s): Adagrasib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
